Current regulatory and legal considerations for follow-on biologics.
作者信息
Kingham R F, Lietzan E
机构信息
Covington & Burling, Washington, DC, USA.
出版信息
Clin Pharmacol Ther. 2008 Nov;84(5):633-5. doi: 10.1038/clpt.2008.159. Epub 2008 Aug 20.
PMID:18716615
Abstract
摘要
相似文献
1
Current regulatory and legal considerations for follow-on biologics.
Clin Pharmacol Ther. 2008 Nov;84(5):633-5. doi: 10.1038/clpt.2008.159. Epub 2008 Aug 20.
2
'Biosimilar' drugs poised to penetrate market.
Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a.
3
US biotech prepares to fight generic biologics.
Nat Biotechnol. 2002 Apr;20(4):322. doi: 10.1038/nbt0402-322a.
4
Path to approval proves rocky for copycat biodrugs.
Nature. 2005 Nov 10;438(7065):154-5. doi: 10.1038/438154a.
5
Bills target biosimilar drugs.
Nature. 2009 Mar 26;458(7237):394-5. doi: 10.1038/458394b.
6
Scientific and legal viability of follow-on protein drugs.
N Engl J Med. 2008 Feb 21;358(8):843-9. doi: 10.1056/NEJMhle0706973.
7
SuperGenerics: a better alternative for biogenerics.
Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0.
8
The ability of current biologics law to accommodate emerging technologies.
Food Drug Law J. 1996;51(3):375-80.
9
Combination products regulation at the FDA.
Clin Pharmacol Ther. 2009 May;85(5):468-70. doi: 10.1038/clpt.2009.28.
10
Zotero 插件